Addendum on expiration of 30-month clock for generic Copaxone: The Hatch-Waxman 30-month clock (during which time the FDA cannot issue a final approval of NVS/MNTA’s Copaxone ANDA) started on 7/11/08 when NVS/MNTA notified Teva of their Paragraph-IV certification for Copaxone (http://www.tevapharm.com/pr/2008/pr_771.asp ). The clock thus expires on January 11, 2011.
After 1/11/11, the FDA can issue a final approval of the Copaxone ANDA whenever the FDA sees fit, without any regard for the status of the Copaxone patent litigation.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.